InvestorsHub Logo
Followers 53
Posts 4314
Boards Moderated 0
Alias Born 02/28/2010

Re: None

Wednesday, 07/30/2014 4:34:26 PM

Wednesday, July 30, 2014 4:34:26 PM

Post# of 1569
Great Numbers for the Second Quarter - $92.1M In Cash versus $152M Market Cap.

SOUTH SAN FRANCISCO, CA, July 30, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the second quarter of 2014 were $7.8 million, compared to $1.0 million during the same period in 2013. The net loss for the second quarter was $8.4 million, or $0.23 per basic and diluted share. This is compared to a net loss for the same period in 2013, of $15.0 million, or $0.58 per basic and diluted share. As of June 30, 2014, cash, cash equivalents and investments totaled $92.1 million.


http://ih.advfn.com/p.php?pid=nmona&article=63088880
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News